Previous 10 | Next 10 |
— Proven Biopharmaceutical Leader Brings Deep, Global Experience with Technical Development, Manufacturing and Supply Chain Operations — Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-t...
DBV Technologies (NASDAQ: DBVT) , a biopharmaceutical company based in France, provided a business update today regarding Viaskin, a potential peanut allergy treatment the company developed that is currently being reviewed by the U.S. Food and Drug Administration (FDA). DBV Technologies expre...
Aimmune Therapeutics (NASDAQ: AIMT) has performed significantly worse than the broader market of late. The company's stock fell by more than 50% during the first quarter of the year, and even though it has rebounded somewhat, Aimmune's shares are still down by 43% year to date. If Aimmune ca...
BioCryst Pharmaceuticals Goes Ahead with Expanded Access Program for Berotralstat BioCryst Pharmaceuticals Inc. ( BCRX ) announced launching its Expanded Access Program for berotralstat. The program will allow physicians to request the drug for hereditary angioedema patients who do not h...
Aimmune Therapeutics ( AIMT +3.6% ) announces positive data from a follow-on study to its Phase 3 PALISADE trial of peanut allergy product Palforzia [peanut (Arachis hypogaea) allergen powder-dnfp]. More news on: Aimmune Therapeutics, Inc., Healthcare stocks news, Stocks on the mov...
— After Two Years of Daily Treatment, More Than 80% of Patients Were Successfully Desensitized to 2000 mg Peanut Protein or Equivalent of About 14 Peanut Kernels— — Majority of Patients Treated Daily Also Reported Lower Rates of Adverse Events and Showed Higher Ra...
— Patients Report Treatment with PALFORZIA™ Is Convenient and Easy to Integrate into Daily Lives — Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, toda...
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in a fireside chat at the Goldman Sachs 41 st Annual G...
-- Important Data on Psychosocial Burden of Peanut Allergy on Children and Caregivers Also to be Presented -- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies, today announced it will pr...
-- Study highlights need to address varying levels of effective disease management, and the associated feelings of uncertainty, stress and isolation across eight European countries – -- Country-specific data show German respondents experience highest levels of anxiety, more than...
News, Short Squeeze, Breakout and More Instantly...
Aimmune Therapeutics Inc. Company Name:
AIMT Stock Symbol:
NASDAQ Market:
— Majority of Patients Experienced Low Rates of Adverse Events, Which Declined in Frequency and Severity with Continued Treatment — — Systemic Allergic Reactions and Epinephrine Use Were Low and Decreased Over Time — Aimmune Therapeutics, ...
-- Peanut Allergy is One of the Most Common Food Allergies in Europe -- -- Up to 1.6% of European Children Live with Potentially Life-Threatening Peanut Allergy -- Aimmune Therapeutics, Inc., a Nestlé Health Science Company, today announced that the European Com...
VEVEY, Switzerland , Sept. 14, 2020 /PRNewswire/ -- Société des Produits Nestlé S.A. ("Nestlé") announced that its wholly-owned subsidiary, SPN Merger Sub, Inc. ("Purchaser"), is commencing today a cash tender offer to purchase all of the outstanding shares of common s...